Recombinant alpha interferon inmetastatic renal cell carcinoma a cooperative phase II study
| Autor: | A. Gibba, Aldo V. Bono, D. Vicini, L. Reali, L. Franch, E. Rigatti, M. Pavone-Macaluso, M. Brausi, C. Benvenuti, Sergio Cosciani-Cunico, F. Coppi, G. Anselmo |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male medicine.medical_specialty Urology medicine.medical_treatment Alpha interferon Alpha (ethology) Phases of clinical research Gastroenterology Renal cell carcinoma Interferon Internal medicine Humans Medicine Carcinoma Renal Cell Interferon alfa Aged Kidney business.industry Remission Induction Immunotherapy Middle Aged medicine.disease Kidney Neoplasms Recombinant Proteins Surgery medicine.anatomical_structure Interferon Type I Drug Evaluation Female business Follow-Up Studies medicine.drug |
| Zdroj: | Urology. 38:60-63 |
| ISSN: | 0090-4295 |
| DOI: | 10.1016/0090-4295(91)80016-z |
| Popis: | A total of 61 evaluable patients with advanced renal cell carcinoma have been treated with 3 × 10 6 IU per square meter of body surface with recombinant alpha 2b interferon three times a week within a Cooperative Phase II Study. Toxic death for terminal renal failure occurred in I patient (1.63%), and toxicities greater than WHO grade 2 were present in 10 cases (16%). The overall response rate after six months of treatment was 13.1% (partial response 4, minor response 4). Two complete responses were obtained at nine and fifteen months (3.3%). Long-lasting stabilization of disease was 13.1 percent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|